167 related articles for article (PubMed ID: 24863086)
1. [The effect of sibutramine on weight loss in obese adolescents].
Franco RR; Cominato L; Damiani D
Arq Bras Endocrinol Metabol; 2014 Apr; 58(3):243-50. PubMed ID: 24863086
[TBL] [Abstract][Full Text] [Related]
2. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
3. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
4. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
[TBL] [Abstract][Full Text] [Related]
5. Effects of sibutramine treatment in obese adolescents: a randomized trial.
Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
7. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
8. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
10. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
Zhao Y; Wang X; Yan Z
Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
[TBL] [Abstract][Full Text] [Related]
11. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
Serrano-Rios M; Melchionda N; Moreno-Carretero E;
Diabet Med; 2002 Feb; 19(2):119-24. PubMed ID: 11874427
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
Halpern A; Leite CC; Herszkowicz N; Barbato A; Costa AP
Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):98-102. PubMed ID: 12118266
[TBL] [Abstract][Full Text] [Related]
14. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
15. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
16. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
[TBL] [Abstract][Full Text] [Related]
17. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Gokcel A; Karakose H; Ertorer EM; Tanaci N; Tutuncu NB; Guvener N
Diabetes Care; 2001 Nov; 24(11):1957-60. PubMed ID: 11679464
[TBL] [Abstract][Full Text] [Related]
18. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
[TBL] [Abstract][Full Text] [Related]
19. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
20. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
Sabuncu T; Ucar E; Birden F; Yasar O
Diabetes Nutr Metab; 2004 Apr; 17(2):103-7. PubMed ID: 15244102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
